DPP-4 Inhibitors: The Other Way to Raise GLP-1

People type one question into a search box and get vague answers back: is Januvia a GLP-1? The honest answer is no, and the reason is more interesting than the yes-or-no suggests. Both drug families act on the same hormone system. A DPP-4 inhibitor raises the GLP-1 the body already makes, a little. A GLP-1 receptor agonist is a drug that occupies the receptor directly, at effective levels the body never produces on its own. Almost every visible difference between the classes, the weight results, the cadence, the indications, follows from that one fork in the road.

This article walks the fork. It covers what the DPP-4 enzyme does and what blocking it accomplishes, which drugs belong to the class and what they are approved for, why the weight story is so different from the injections, the warnings these labels carry, and the strange historical detail that the entire GLP-1 era exists because of this enzyme.

The enzyme, and what blocking it does

The story starts with incretin hormones, including GLP-1 and GIP, which the intestine releases throughout the day and which rise in response to a meal. For the hormone itself, see What Is GLP-1, the Hormone Behind the Headlines?, and for the second member of the family, GIP and Glucagon: Why Newer Drugs Hit More Than One Receptor.

The body treats these hormones as disposable. They are rapidly inactivated by an enzyme called DPP-4, which slices them up within moments of release. A DPP-4 inhibitor slows that inactivation, so the active hormones the intestine already makes last longer. In people with type 2 diabetes, sitagliptin inhibited DPP-4 activity over a 24 hour period, and after a meal or a glucose load this produced a 2 to 3 fold increase in circulating levels of active GLP-1 and GIP.

The downstream effect is glucose dependent, which is the quiet star of the mechanism. When blood glucose is normal or high, GLP-1 and GIP increase insulin release and GLP-1 lowers glucagon. The system responds to food rather than running constantly, which is a large part of why this class has the side effect profile it has.

The drugs in the class, and what they treat

Four members of the class are FDA approved in the United States: sitagliptin, marketed as Januvia by Merck; saxagliptin, first sold as Onglyza and now listed in the United States under generic labels; linagliptin, marketed as Tradjenta by Boehringer Ingelheim; and alogliptin, marketed as Nesina by Takeda. All are oral tablets taken once daily. The recommended dose of Januvia is 100 mg once daily; alogliptin's dose is reduced in renal impairment, to 12.5 mg once daily in moderate impairment and 6.25 mg once daily in severe impairment and in end stage renal disease requiring dialysis.

The indication is about blood sugar. Januvia, Tradjenta and Nesina are each indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. None of them is approved for weight loss, and none carries a cardiovascular risk reduction indication. The limitations of use on the sitagliptin label add two boundaries: it should not be used in patients with type 1 diabetes, and it has not been studied in patients with a history of pancreatitis.

Why the weight results differ so much

Here is the contrast that is the entire point of this article. A DPP-4 inhibitor raises the body's own GLP-1 by roughly two to three times, within the physiologic range. A GLP-1 receptor agonist is a drug that occupies the receptor directly, at far higher effective levels than the body ever produces. Two to three times your own after-meal GLP-1 is simply not the same order of magnitude as a weekly injection, and no multiplier for the agonists belongs in a sentence like this one, because it is not a like-for-like comparison.

The weight data bear that out in the least dramatic way possible. Per the Januvia label's clinical studies section, body weight did not increase from baseline with Januvia therapy in either study, compared to a small reduction in patients given placebo. In a 52 week comparison against glipizide, an older sulfonylurea, patients on sitagliptin had a mean decrease in body weight of 1.5 kg while the glipizide group gained a mean 1.1 kg, and in that same study hypoglycemia occurred in 4.9 percent of the sitagliptin group and 32.0 percent of the glipizide group. Added to pioglitazone in one study, sitagliptin was associated with a mean increase of 1.1 kg relative to pioglitazone alone. The honest summary of all of it is weight neutral, not weight losing.

That is not a failure. A person taking sitagliptin for blood sugar is not on an inferior weight-loss drug; they are not on a weight-loss drug at all, and comparing their tablet to a weight-management injection is a category error. The tablet does a different job, and metformin, the most common companion in type 2 diabetes, is a third job entirely; that pairing has its own guide in Metformin Plus a GLP-1: The Most Common Pairing.

GLP 1 Tracker AppWhatever the treatment plan holds, a private, dated record of doses, side effects and weight, kept on your own phone. Get the app

The warnings on these labels

Every drug label has a Warnings and Precautions section, and the DPP-4 class has entries worth naming. Pancreatitis leads them: postmarketing reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, with the label directing that the drug be discontinued promptly if pancreatitis is suspected. Acute renal failure has been reported postmarketing, sometimes requiring dialysis, and hypoglycemia can occur when these tablets are combined with insulin or an insulin secretagogue. Bullous pemphigoid, a blistering skin condition, appears in the postmarketing reports as well, in cases that required hospitalization.

Two warnings deserve their own paragraphs. Heart failure: an association between DPP-4 inhibitor treatment and heart failure was observed in cardiovascular outcomes trials for two members of the class, and the Nesina label names its own trial, EXAMINE, in which 106 patients, 3.9 percent, on alogliptin and 89, 3.3 percent, on placebo were hospitalized for congestive heart failure. And severe and disabling arthralgia: postmarketing reports describe joint pain onset from one day to years after starting, with relief on discontinuation and recurrence in some patients on rechallenge.

That arthralgia warning makes for a genuinely useful comparison, because the two drug families that touch the same hormone have two different joint stories. As documented in Joint Pain on a GLP-1: What Is Reported, the GLP-1 receptor agonist labels do not list arthralgia as an adverse reaction, while the DPP-4 inhibitor labels carry the explicit warning. Same hormone system, different drugs, different label text, and one more reason the answer to is Januvia a GLP-1 has to be no rather than close enough.

Where the whole GLP-1 story began

There is a historical twist that ties the two families together. The GLP-1 era began with exendin-4, a compound identified in Gila monster venom in the early 1990s, and the reason it mattered at all was this enzyme: exendin-4 resists rapid breakdown by DPP-4, so it lasts hours instead of the minutes the body's own GLP-1 gets. The synthetic version became exenatide, the first GLP-1 receptor agonist, and everything from liraglutide to semaglutide to tirzepatide followed. The full story, and our mascot's place in it, is in The Gila Monster Behind GLP-1 Drugs (and Our Mascot, Gigi).

So the classes are cousins, not rivals. One family protects the hormone the body makes from the enzyme that dismantles it; the other replaces the hormone at the receptor entirely. Which one any person should be taking is among the most individual questions in medicine, and it belongs to the prescriber who can see the whole chart, not to an article. What an article can do is make the vocabulary stop blurring, so the question a reader brings to that conversation is the right one.